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Since the first description of acute promyelocytic leuke-
mia (APL) in 1957 as the most malignant form of acute
leukemia, several developments have paved the way to
make this disease the most curable leukemia in adults and
change the paradigm of cancer treatment. Therapy of APL
was pioneered by Bernard et al in 1973 demonstrating a
striking sensitivity to daunorubicin, probably related to
significantly lower P-glycoprotein expression observed in
APL cells compared to other subtypes of acute myeloid
leukemia (AML).
The incorporation of ATRA, a noncytotoxic differentiating
agent that is regarded as the first differentiation therapy
has changed dramatically the management, outcome, and
prognosis of APL.
ATRA was first introduced to clinical use for the treatment
of APL in 1986. Since then, randomized studies in many
centers around the world document a rising CR rate, a
decrease in severe adverse effects, and a prolongation of
remission duration. ATRA combined with anthracycline-
based chemotherapy can achieve CR in 90–95% of
patients with APL and cure the disease in 70–75% of the
cases. Combination therapy with ATRA and chemothera-
peutic agents should now be considered as a standard
treatment of APL.
Over the last decade, tremendous efforts have been made
to elucidate the molecular genesis of APL, as well as the
mechanism of action of ATRA. The mechanism of action
of ATRA can be summarized as follows: 1. The binding of
ATRA to RAR receptors causes degradation of PML-RAR
protein through the ubiquitin-proteosome and caspase
system, leading to restoration of terminal differentiation
of promyelocytes; 2. Exposure of APL cells to ATRA in
vitro or in vivo induces relocalization of PML and restores
the normal structure of PODs; and 3. Under the action of
ATRA, CoR is dissociated from the repressive complex,
whereas CoA (coactivator) is recruited to the complex. As
a result, the repression of transcriptional activation of tar-
get genes is relieved and the differentiation of promyelo-
cytes is restored.
Treatment of APL by arsenic compounds represents a suc-
cessful example of apoptosis induction therapy of acute
leukemia. As2O3 exerts dual effects on APL cells. Studies in
vitro with NB4 cells showed that a higher concentration of
As2O3 (0.5–1.0 M) induced apoptosis with typical mor-
phological changes, DNA laddering on agarose gel elec-
trophoresis, appearance of an apoptotic peak on flow
cytometric analysis, and increased expression of annexin
V on the cell surface membrane. At lower concentrations,
As2O3 can induce APL cells to partially differentiate along
the granulocytic pathway.
Synergistic effect of ATRA and As2O3 was confirmed by
several research works in vivo and in vitro. The first clini-
cal trial was completed by SIH in 2001. CR rate was same
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as ATRA or As2O3 alone, but the median day to CR was
very short, only 26 days, and OS and DFS were much bet-
ter than ATRA or As2O3 alone. Now timing and dose of
As2O3 combined with ATRA in newly diagnosed APL
patients need to be confirmed.
Recently, several genetic and phenotypic characteristics of
acute promyelocytic leukemia (APL) blasts have been
demonstrated. These include the PML/RAR fusion and
the transcription co-repressor complex recruited at the
promoter of target genes by the hybrid protein, the intense
and homogeneous expression of the CD33 antigen, and
absence of multidrug resistance-related phenotype, a fre-
quently mutated and constitutively activated FLT3 recep-
tor. Such genotypic and phenotypic features are targeted
by agents currently in use in front-line therapy or at
relapse (i.e., retinoids, As2O3, anthracyclines and anti-
CD33 monoclonal antibodies), and by novel agents that
many find a place in future treatments such as histone
deacetylase and FLT3 inhibitors.Page 2 of 2
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